FDA readies for cough/cold meeting
This article was originally published in The Tan Sheet
Executive Summary
An FDA spokeswoman said Sept. 26 the agenda for the Oct. 2 meeting on OTC cough/cold products has yet to be finalized but approximately 28 parties are scheduled to make presentations. Since announcing the meeting Aug. 25, FDA has received comments from two parties, including Wayne Snodgrass, one of the petitioners whose filing led to FDA's review of pediatric cough/cold safety (1"The Tan Sheet" Oct. 22, 2007, p. 3)
You may also be interested in...
FDA Panel Narrowly Votes Against Cough/Cold Drugs For Children Up To Age 6
An FDA advisory panel decided in split votes Oct. 19 to recommend immediately that all OTC cough/cold medicines should not be used for 2-to 5-year-old children but are safe for 6- to 12-year-olds
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.